The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass

Journal of Extra-Corporeal Technology

Volumn 29, Issue 3, 1997, Pages 114-122

  Stammers, Alfred H ^a   Huffman, Suzanne ^a   Alonso, Anselmo ^a   Fristoe, Lance W ^a   Hill, Gary ^b   Casebeer, Dana ^a   Diego, Robert P ^b   Song, Zuorui ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aprotinin; Cardiopulmonary bypass; Coagulation; Inflammation; Serine protease inhibition

Indexed keywords

APROTININ; D DIMER; FIBRIN DEGRADATION PRODUCT; LEUKOCYTE ELASTASE; PLACEBO;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LUNG FUNCTION; MALE; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030879875     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. N Eng J Med. 1981; 304:497-503.
2. Svennevig JL, Geiran OR, Karsen H. et al. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator J Thorac Cardiovasc Surg. 1993; 106: 466-72.
3. Edmunds LH. Blood-surface interactions during cardiopulmonary bypass. J Card Surg. 1993;8:404-10.
4. Allen SM. Leukocyte depletion in cardiothoracic surgery. Perfusion. 1996; 11:270-7.
5. Hill, GE, Pohorecki R, Alonso A, Rennard SI, Robbins, RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83:696-700.
6. Hill GE, Alonso A, Spurzem RJR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658-62.
7. Takaori M, Fukui A, Kimura K, et al. Hemostatic mechanism associated with aprotinin during and after extracorporeal circulation for cardiac and great vessel surgery. Masui. 1995; 44: 1661-6.
8. Wendel HP, Heller W, Gallimore MJ, Hoffmeister HE. Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model. Blood Coagul Fibrinolysis. 1994;5:673-8.
9. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: Cytokines and receptors. J Cardiovasc Pharmacol. 1996;27(Suppl. 1):S1-5.
10. Daily PO, Lamphere JA, Dembitsky WP, et al. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion in patients undergoing first-time coronary artery bypass grafting. A randomized double-blind study. J Thorac Cardiovasc Surg. 1994; 108:99-108.
11. Horrow JC, Van Riper DF, Strong MD, et al. Hemostatic effects of tranexamic acid during cardiac surgery. Circulation. 1991;84: 2063-70.
12. Speekenbrink RG, Wildevuur CR, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg. 1996;112: 523-30.
13. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 1996;62: 1659-67.
14. Royston D. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol. 1996;27(Suppl. 1):S42-9.
15. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation. 1992;86: II405-9.
16. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vase Anesth. 1991;5:467-74
17. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass-effects on the Hageman factor (FXII) - Kallikrein system and blood loss. Blood Coagul Fibrinolysis. 1992;3:99-104.
18. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drug Evaluation. 1995; 49:954-83.
19. Becket MA, Brannan J, Fleming J, Taylor KM. The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass. Perfusion. 1996; 11: 278-80.
20. Wachtfogel YT, Hack CE, Nuijens JH, et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol. 1995; 268: H1352-7.
21. Seghaye MC, Duchateau J, Grabitz RG, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg. 1996; 61: 1205-11.
22. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2: 1289-91.
23. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, doubleblind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995;92: 2236-44.
24. Schonberger JP, Woolley S, Tavilla G, et al. Efficacy and safety of a blood conservation program including low-dose aprotinin in routine myocardial revascularization. J Cardiovasc Surg Torino. 1996;37: 35-44.
25. Shinfeld A, Zippel D, Lavee J, et al. Aprotinin improves hemostasis after cardiopulmonary bypass better than singledonor platelet concentrate. Ann Thorac Surg. 1995;59:872-6.
26. Levy JH, Bailey JM, Salmenpera M B. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994; 80: 1013-18.
27. Taylor KM. Improved outcome for seriously ill open heart patients: Focus on reoperation and endocarditis. J Heart Lung Transplant. 1993;12:S14-8.
28. Rao PS, Palazzo RS, Bocchieri KA, et al. Aprotinin protects against myocardial and oxidant formation and endothelial cell damage during open heart surgery. Ann N Y Acad Sci. 1996;793:514-6.
29. Broche VF, Suarez AR, Olembre E, et al. Aprotinin effects related to oxidative stress in cardiosurgery with mechanical cardiorespiratory support (CMCS). Ann NY Acad Sci. 1996;793:521-4.
30. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990; 76: 1680-97.
31. Mannucci L, Gerometta PS, Mussoni L, et al. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin. Thromb Haemost. 1995;73:356-61.
32. Stammers AH, Rasmussen CA, Kratz JM. Hemorrhagic effects of post cardiopulmonary bypass fibrinolysis. J Extra-Corpor Technol. 1993;25:133-9.
33. Lu H, Du-Buit C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost. 1994;72: 438-43.
34. Boldt J, Schindler E, Welters I, et al. The effect of the anticoagulation regimen on endothelial-related coagulation in cardiac surgery patients. Anaesthesia. 1995;50:954-60.
35. Fresbelius S, Nydahl S, Swedenborg J. Coagulant and non-coagulant thrombin enzymatic activity on the endothelium. Blood Coag Fibrin. 1990;1:285-92.
36. Boldt J, Schindler E, Knothe C, et al. Does aprotinin influence endothelial-associated coagulation in cardiac surgery? J Cardiothorac Vase Anesth. 1994;8:527-31.
37. Gillinov AM, Redmond JM, Zehr KJ, et al. Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg. 1994;57:126-33.
38. Murata A, Toda H, Uda K, et al. Protective effect of recombinant neutrophil elastase inhibitor (R-020) on sepsisinduced organ injury in rat. Inflammation. 1994;18:337-47.
39. Lord RA, Roath OS, Thompson JF, Chant AD, Francis JL. Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg. 1992;79:517-21.
40. van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-5.
41. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-9.